216 related articles for article (PubMed ID: 37183261)
21. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
[TBL] [Abstract][Full Text] [Related]
22. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
Li Y; Feng Y; Luo F; Peng G; Li Y
Front Immunol; 2022; 13():1089792. PubMed ID: 36726969
[TBL] [Abstract][Full Text] [Related]
23. A Novel TAF-Related Signature Based on ECM Remodeling Genes Predicts Glioma Prognosis.
Wang LJ; Lv P; Lou Y
Front Oncol; 2022; 12():862723. PubMed ID: 35574375
[TBL] [Abstract][Full Text] [Related]
24. Identification of potential biomarkers related to glioma survival by gene expression profile analysis.
Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY
BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of a Stemness Index-Associated Signature in Primary Lower-Grade Glioma.
Zhang M; Wang X; Chen X; Guo F; Hong J
Front Genet; 2020; 11():441. PubMed ID: 32431729
[TBL] [Abstract][Full Text] [Related]
26. A Risk Score Signature Consisting of Six Immune Genes Predicts Overall Survival in Patients with Lower-Grade Gliomas.
Wu Y; Peng Z; Gu S; Wang H; Xiang W
Comput Math Methods Med; 2022; 2022():2558548. PubMed ID: 35186111
[TBL] [Abstract][Full Text] [Related]
27. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
28. The promising novel biomarkers and candidate small molecule drugs in lower-grade glioma: Evidence from bioinformatics analysis of high-throughput data.
Zhang B; Wu Q; Xu R; Hu X; Sun Y; Wang Q; Ju F; Ren S; Zhang C; Qi F; Ma Q; Wang Z; Zhou YL
J Cell Biochem; 2019 Sep; 120(9):15106-15118. PubMed ID: 31020692
[TBL] [Abstract][Full Text] [Related]
29. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
[TBL] [Abstract][Full Text] [Related]
30. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.
Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J
Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778
[No Abstract] [Full Text] [Related]
31. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
32. Bioinformatics analysis of C3 in brain low-grade gliomas as potential therapeutic target and promoting immune cell infiltration.
Wu S; Miao K; Wang L; Ma Y; Wu X
Med Oncol; 2022 Jan; 39(2):27. PubMed ID: 35018510
[TBL] [Abstract][Full Text] [Related]
33. Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas.
Kuang Y; Jiang B; Zhu H; Zhou Y; Huang H; Li C; Zhang W; Li X; Cao Y
Front Immunol; 2023; 14():1102094. PubMed ID: 37153540
[TBL] [Abstract][Full Text] [Related]
34. A Novel Four-Gene Signature Associated With Immune Checkpoint for Predicting Prognosis in Lower-Grade Glioma.
Xiao Y; Cui G; Ren X; Hao J; Zhang Y; Yang X; Wang Z; Zhu X; Wang H; Hao C; Duan H
Front Oncol; 2020; 10():605737. PubMed ID: 33381460
[TBL] [Abstract][Full Text] [Related]
35. Identification of genes related to low-grade glioma progression and prognosis based on integrated transcriptome analysis.
Jiang Y; He J; Guo Y; Tao H; Pu F; Li Y
J Cell Biochem; 2020 Jun; 121(5-6):3099-3111. PubMed ID: 31886582
[TBL] [Abstract][Full Text] [Related]
36. Radiogenomic landscape: Assessment of specific phagocytosis regulators in lower-grade gliomas.
Maimaiti A; Abulaiti A; Tang B; Dilixiati Y; Li X; Yakufu S; Wang Y; Jiang L; Shao H
Exp Biol Med (Maywood); 2023 Dec; 248(23):2289-2303. PubMed ID: 38062999
[TBL] [Abstract][Full Text] [Related]
37. A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma.
Zhang JH; Hou R; Pan Y; Gao Y; Yang Y; Tian W; Zhu YB
J Cell Mol Med; 2020 Jul; 24(13):7504-7514. PubMed ID: 32412186
[TBL] [Abstract][Full Text] [Related]
38. Cuprotosis clusters predict prognosis and immunotherapy response in low-grade glioma.
Zhu W; Chen Z; Fu M; Li Q; Chen X; Li X; Luo N; Tang W; Yang F; Zhang Y; Zhang Y; Peng X; Hu G
Apoptosis; 2024 Feb; 29(1-2):169-190. PubMed ID: 37713112
[TBL] [Abstract][Full Text] [Related]
39. Identification of an Inflammatory Response-Related Gene Signature to Predict Survival and Immune Status in Glioma Patients.
Yan Z; Gao Y; Yu J; Shen Z; Bu X
J Immunol Res; 2022; 2022():8972730. PubMed ID: 35647198
[TBL] [Abstract][Full Text] [Related]
40. Discovery of 5-Signature Predicting Survival of Patients with Lower-Grade Glioma.
Xiao H; Bai J; Yan M; Ji K; Tian W; Liu D; Ning T; Liu X; Zou J
World Neurosurg; 2019 Jun; 126():e765-e772. PubMed ID: 30853516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
